Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00426998
Status:
COMPLETED
Last Update Posted:
2007-01-26
First Post:
2007-01-24
Brief Title:
Combination Bevacizumab and Verteporfin Two Different Sequences of Treatmentin Neovascular AMD
Sponsor:
Retinal Consultants Medical Group
Organization:
Retinal Consultants Medical Group
Study Overview
Official Title:
A 24 Month Randomized Double-Masked Single Center Phase II Study Comparing Photodynamic Therapy With Verteporfin VisudynePlus Two Different Timing Regimens of Intravitreal Bevacizumab Avastin Given 1 Week Prior to or 1 Week Following Photodynamic Therapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization CNV due to age-related macular degeneration AMD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None